Copper-indomethacinate associated with zwitterionic phospholipids prevents enteropathy in rats: Effect on inducible no synthase

Digestive Diseases and Sciences

Volumn 44, Issue 5, 1999, Pages 991-999

  Bertrand, Viviane ^b   Guessous, Fadila ^b   Le Roy, Anne Laure ^b   Viossat, Bernard ^b   Fessi, Hatem ^b   El Abbouyi, Ahmed ^b   Giroud, Jean Paul ^b   Roch Arveiller, Monique ^a  

^a Pharmacologie Hôpital Cochin ^*  (France)

^b NONE

Author keywords

Indomethacin; Inducible nitric oxide synthase; Liposomes; Myeloperoxidase; Nanocapsules; Nonsteroidal antiinflammatory drugs

Indexed keywords

COPPER COMPLEX; INDOMETACIN; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG MECHANISM; ENTEROPATHY; ENZYME ACTIVITY; ENZYME RELEASE; ILEUM; JEJUNUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COPPER; INDOMETHACIN; INTESTINE, SMALL; JEJUNUM; LIPOSOMES; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; ORGANOMETALLIC COMPOUNDS; PEROXIDASE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; ULCER;

EID: 0010368222     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026668816189     Document Type: Article

References (46)

1. Garner A: Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and disease. Scand J Gastroenterol 27:83-89, 1992
2. Bjarnasson I, Hayllar J, Mac Pherson AJ, Russel AS: Side effects of nonsteroid anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104:1832-1847, 1993
3. Yamada Y, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB: Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17:641-662, 1993
4. 4 synthesis. Gastroenterology 102:18-27, 1992
5. Davies NM, Wright MR, Jamali F: Antiinflammatory drug-induced small intestinal permeability: The rat is a suitable model. Pharmacol Res 11:1652-1656, 1994
6. Hills BA, Butler BD, Lichtenberger LM: Gastric mucosal barrier: Hydrophobic lining to the lumen of the stomach. Am J Physiol 244:G561-G568, 1983
7. Anthony A, Pounder RE, Dhillon AP, Wakefield AJ: Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 41:763-770, 1997
8. Lichtenberger LM, Wang ZM, Giraud MN, Romero JJ, Barreto JC: Effect of naproxen gastric mucosal hydrophobicity. Gastroenterology 108:A149, 1995
9. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, Barretto JC: Non-steroidal anti-inflammatory drugs (NSAIDs) associated with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med 1:154-158, 1995
10. Goddard PJ, Hills BA, Lichtenberger LM: Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity? Am J Physiol 252:G421-G430, 1987
11. Lichtenberger LM, Graziani LA, Dial EJ, Butler BD, Hills DA: Role of surface-active phospholipids in gastric cytoprotection. Science 219:1327-1329, 1983
12. Moncada S, Higgs A: The L-arginine nitric oxide pathway. N Engl J Med 27:2002-2012, 1993
13. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P: Regulation of prostaglandin production by nitric oxide: An in-vivo analysis. Br J Pharmacol 114:1171-1178, 1995
14. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90:7240-7244, 1993
15. Salvemini D, Misko TP, Masferrer J, Seibert K, Currie MG, Needleman P: In Biology of Nitric Oxide, vol 4. S Moncada, M Feelish, R Busse (eds). London, Portland Press, 1995, chap 8, pp 304-315
16. Alican I, Kubes P: A critical role for nitric oxide in intestinal barrier function and dysfunction. Am J Physiol 270:G225-G237, 1996
17. Mc Call TB, Boughton-Smith NK, Palmer RM, Whittle BJR, Moncada S: Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J 261:293-296, 1989
18. Wink DA, Cook JA, Pacelli R, Liebmann J, Krishna MC, Mitchell JB: Nitric oxide (NO) protects against cellular damage by reactive oxygen species. Toxicol Lett 82/83:221-226, 1995
19. Wallace JL, Reuter BK, Cicala C, MC Knight W, Grisham MB, Cirino G: A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 257:249-255, 1994
20. Wallace JL, Reuter BK, Cirino G: Nitric-oxide-releasing NSAIDs: A novel approach for reducing gastrointestinal toxicity. Gastroenterol Hepatol 9:S40-S44, 1994
21. Bertrand V, Guimbaud R, Tulliez M, Mauping C, Sogni P, Couturier D, Giroud JP, Chaussade S, Chauvelot-Moadon L: Increase in tumour necrosis factor-α production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 124:1385-1394, 1998
22. Bertrand V, Guimbaud R, Sogni P, Lamrani A, Mauprivez C, Giroud JP, Couturei D, Chauvelot-Moadon L, Chaussade S: Role of tumour necrosis factor-α and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity. Eur J Pharmacol 356:245-253, 1998
23. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacal H, Price AB, McPherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnassan I: Mitochondrial damage: A possible mechanism of the "topical" phase of NSAID induced injury in the rat intestine. Gut 41:344-353, 1997
24. Kurose I, Miura S, Higuchi H, Watanabe N, Kamejaya Y, Tkaishi H, Tomita K, Fukumusa D, Kato S, Ishü H: Increased nitric oxide synthase activity as a cause of mitochondrial dysfunction in rat hepatocytes: role of TNF-α. Hepatology 24:1185-1192, 1996
25. Sorenson JRJ: Copper chelates as possible active forms of antiarthritic agents. J Med Chem 19:135-148, 1976
26. Sorenson JR: Copper-complexes offer physiologic approach to treatment of ulcers. In Ulcer Diseases. New Aspects of Pathogenesis and Pharmacology. S Szabo, CJ Pfeiffer (eds). Boca Raton, Florida, CRC Press, 1989, pp 357-372
27. Roch-Arveiller M, Pham Huy D, Maman L, Giroud JP, Sorenson JRJ: Nonsteroidal anti-inflammatory drug-copper complex modulation of polymorphonuclear leukocyte migration. Biochem Pharmacol 39:569-574, 1990
28. Roch-Arveiller M, Revelant V, Pham Huy D, Mamau L, Fontague J, Sorenson JRJ, Giroud JP: Effects of some nonsteroidal anti-inflammatory drug-copper complexes on polymorphonuclear leukocyte oxidative metabolism. Agents Actions 31:65-71, 1990
29. Weissenborn U, Maedge S, Buettner D, Swing KF: Indomethacin induced gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology 30:32-39, 1985
30. Stainmesse S, Fessi H, Devissaguet JP, Puisieux F: Procédés de préparation de systèmes colloidaux dispersibles de lipides amphiphiles sous forme de liposomes submicroniques, European patent no. 894018571
31. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S: Nanocapsule formation by interfacial polymer deposition following solvent deplacement. Int J Pharmacol 55:R1-R4, 1989
32. Wallace JL, Mc Knight W, Miyasaka M, Tamatano T, Paulson J, Anderson DC, Granger DN, Kuber P: Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 265:G993-G998, 1993
33. Maehly AC, Chance B: The assay of catalases and peroxidases. In Methods of Biochemical Analysis. D Glick (ed). New York, Interscience, 1954, pp 357-408
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
35. Bush PA, Gonzalez NE, Griscavage JM, Ignarro LJ: Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from L-arginine. Biochem Biophys Res Commun 185:960-966, 1992
36. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS: Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochemistry 27:8706-8711, 1988
37. Worthington Biochemical Corp: Worthington Enzyme Manual. Worthington Biochemical Corp, Freehold, New Jersey. 1972, 43 pp
38. Scarpignato C: NSAID-induced gastro-duodenal damage: from pathogenesis to prevention. In Recent Advances in the Pathophysiology of Gastrointestinal and Liver Diseases. JP Galmiche, J Gournay (eds). Paris, John Libbey Eurotext, 1997, pp 47-84
39. Wallace JL, Keenan Ch, Granger DN: Gastric ulceration by non-steroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 259:G462-G467, 1990
40. Shoehgen EC, Godin-Ostro E, Fielder FG, Ginsberg RS, Slusher MA, Weiner AL: Encapsulation of indomethacin in liposomes provides protection against both gastric and intestinal ulceration when orally administered to rats. Arthritis Rheum 31:412-421, 1989
41. Ammoury N, Fessi H, Devissaguet JP, Dubrasquet M, Benita S: Jejunal absorption, pharmacological activity and pharmacokinetic evaluation of indomcthacin loaded poly (D, L-lactide) and poly(isobutylcyanoacrylate) nanocapsules in rats. Pharm Res 8:101-105, 1991
42. Ammoury N, Dubrasquet M, Fessi H, Devissaguet JP, Puisieux F, Benita S: Indomethacin-loaded poly(D,L-lactide) nanocapsules: Protection from gastrointestinal ulceration and antiinflammatory activity evaluation in rats. Clin Mater 13:121-130, 1993
43. Konturek SK, Konturek PC: Role of nitric oxide in the digestive system. Digestion 51:1-13, 1995
44. Kubes P, Wallace JL: Nitric oxide as a mediator of gastrointestinal mucosal injury? Mediators Inflamm 4:397-405, 1995
45. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 109:524-530, 1995
46. Smalley WE, Griffin MR: The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 25:373-396, 1996